Financial Performance - The company's revenue for Q1 2023 was CNY 106,949,889.42, representing a 14.87% increase compared to CNY 93,108,589.87 in the same period last year[4] - Net profit attributable to shareholders was CNY 24,997,456.97, a 2.57% increase from CNY 24,371,104.61 year-over-year[4] - Basic earnings per share rose to CNY 0.49, up 2.08% from CNY 0.48 in the same quarter last year[5] - Total operating revenue for Q1 2023 was CNY 106,949,889.42, an increase of 14.8% compared to CNY 93,108,589.87 in the same period last year[22] - Net profit for Q1 2023 reached CNY 24,997,456.97, representing a slight increase of 2.6% from CNY 24,371,104.61 in Q1 2022[23] - The net profit attributable to the parent company for Q1 2023 is CNY 24,997,456.97, compared to CNY 24,371,104.61 in Q1 2022, representing an increase of approximately 2.58%[24] - The total comprehensive income for Q1 2023 is CNY 24,997,456.97, which is an increase from CNY 24,371,104.61 in Q1 2022, reflecting a growth of approximately 2.58%[24] Cash Flow - The net cash flow from operating activities increased by 116.39%, reaching CNY 3,284,551.58, compared to a negative cash flow of CNY 20,034,757.26 in the previous year[4] - Cash inflow from operating activities for Q1 2023 is CNY 77,098,817.83, compared to CNY 53,309,450.52 in Q1 2022, reflecting an increase of approximately 44.6%[25] - The net cash flow from operating activities for Q1 2023 is CNY 3,284,551.58, a significant recovery from a net outflow of CNY 20,034,757.26 in Q1 2022[27] - Cash outflow from investing activities in Q1 2023 amounts to CNY 8,641,067.69, compared to CNY 2,390,671.90 in Q1 2022, indicating an increase of approximately 261.5%[27] - The net cash flow from investing activities for Q1 2023 is -CNY 8,523,067.69, worsening from -CNY 2,390,671.90 in Q1 2022[27] - Cash and cash equivalents at the end of Q1 2023 were CNY 241,762,827.78, down from CNY 247,190,625.65 at the beginning of the year, a decrease of 2.0%[18] - The cash and cash equivalents at the end of Q1 2023 stand at CNY 233,810,327.78, compared to CNY 161,787,526.03 at the end of Q1 2022, showing an increase of approximately 44.4%[28] - The impact of exchange rate changes on cash and cash equivalents in Q1 2023 is -CNY 189,281.76, compared to a positive impact of CNY 499,360.23 in Q1 2022[28] Assets and Liabilities - Total assets increased by 3.57% to CNY 585,655,494.81 from CNY 565,484,619.74 at the end of the previous year[5] - Accounts receivable increased to CNY 54,173,579.47 from CNY 43,551,326.57 at the beginning of the year, reflecting a growth of 24.5%[18] - Inventory decreased to CNY 130,888,089.85 from CNY 142,646,529.87, a decline of 8.3%[18] - Total assets as of the end of Q1 2023 were CNY 585,655,494.81, up from CNY 565,484,619.74 at the beginning of the year, indicating a growth of 3.0%[20] - Total liabilities decreased to CNY 91,292,298.66 from CNY 96,447,302.50, a reduction of 5.4%[20] Research and Development - Research and development expenses grew by 35.60%, totaling CNY 78,790, reflecting the company's increased investment in R&D[10] - Research and development expenses for Q1 2023 were CNY 3,001,211.35, an increase of 35.5% compared to CNY 2,213,356.38 in Q1 2022[23] Operational Changes - Accounts receivable financing increased by 437.31%, amounting to CNY 16,382,800, primarily due to increased sales and a shift to bill settlements with major clients[9] - The company reported a 68.15% increase in taxes and surcharges, amounting to CNY 309,200, due to higher export sales[10] - The company plans to expand its production capacity with an investment in a new production line for atorvastatin calcium, which is expected to increase output by 200 tons annually[9] - The company has not reported any new product developments or market expansion strategies in the current quarter[29] Employee Compensation - The company reported a decrease in employee compensation payable to CNY 6,224,903.11 from CNY 12,485,720.76, a decline of 50.1%[19] Return on Equity - The weighted average return on equity decreased to 5.19% from 6.53% in the previous year[5]
海森药业(001367) - 2023 Q1 - 季度财报